ArticleCancer control : journal of the Moffitt Cancer Center
Effects of Intermittent Fasting on Response to Tyrosine Kinase Inhibitors (TKIs) in Patients With Chronic Myeloid Leukemia: An Outcome of European LeukemiaNet Project.
Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- The Clinical Impact of Time-restricted Eating on Cancer: A Systematic Review.Nutrition reviews · 2025Pooled it
- Avascular necrosis in patients with chronic myeloid leukemia: A systematic review.Acta bio-medica : Atenei Parmensis · 2022Pooled it
- Osteolytic bone lesions in patients with primary myelofibrosis: A systematic review.Acta bio-medica : Atenei Parmensis · 2022Pooled it
- Myasthenia Gravis and Myeloproliferative Neoplasms - Mere Association or Paraneoplastic Neurologic Syndrome: A Mini-Review.Acta bio-medica : Atenei Parmensis · 2022Pooled it
- A deep dive into the surgical and pharmacological considerations of obesity in chronic myeloid leukemia: a narrative review.Frontiers in oncology · 2025Review
- The oncobiome; what, so what, now what?Microbiome research reports · 2025Review
- The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based Review.Cancers · 2024Review
- Intermittent fasting and its impact on toxicities, symptoms and quality of life in patients on active cancer treatment.Cancer treatment reviews · 2024Review
- Viral Infections and Incidence of Reactivations in Chronic Myeloid Leukemia Patients.Oncology · 2024Review
- Intermittent fasting interventions to leverage metabolic and circadian mechanisms for cancer treatment and supportive care outcomes.Journal of the National Cancer Institute. Monographs · 2023Article
- Applications of Machine Learning in Chronic Myeloid Leukemia.Diagnostics (Basel, Switzerland) · 2023Review
- Radioactive Iodine-Induced Chronic Myeloid Leukemia in a Patient With Graves' Disease: A Case Report.Cureus · 2023Article
- Intermittent fasting and immunomodulatory effects: A systematic review.Frontiers in nutrition · 2023Article
- Tyrosine Kinase Inhibitors in pediatric chronic myeloid leukemia: a focused review of clinical trials.Frontiers in oncology · 2023Review
- Review
- Patient with clinical celiac disease mimicking triple-negative essential thrombocythemia.Clinical case reports · 2022Article
- Warm Autoimmune Hemolytic Anemia as First Presentation of Chronic Myeloid Leukemia: A Case Report.Case reports in oncologyArticle
- Clinicopathological Variables and Outcome in Chronic Myeloid Leukemia Associated With BCR-ABL1 Transcript Type and Body Weight: An Outcome of European LeukemiaNet Project.Cancer control : journal of the Moffitt Cancer CenterArticle
- Cervical Lymphadenopathy in Concomitant CML and Tuberculosis: A Case Report.Case reports in oncologyArticle
- Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The overall survival of patients with Chronic Myeloid Leukemia (CML) treated by using tyrosine kinase inhibitors (TKIs) is very close to that of the healthy population. However, little is known about the effect of specific measures such as intermittent fasting, especially during Ramadan period. A 3-year retrospective study was conducted to evaluate the effect of fasting on patients with CML receiving TKIs by evaluating certain clinical, hematological, and molecular parameters. A total of 49 patients were eligible, with a median age of 46 years (range: 22-86), of these 36 (73.5%) were males and 13 (26.5%) were females. Twenty-seven (55%) patients are Middle Eastern, while 16 (32.7%) from the Indian subcontinent, and 6 (12.3%) Africans. Imatinib was the most common TKI; used in 25 patients (51%). The mean White blood cells (WBCs), neutrophils, and BCR-ABL were found to be reduced after fasting compared to before and during with statistical difference. The use of TKIs while fasting did not result in significant changes in hematological nor BCR-ABL levels in our study. Patients who wish to practice intermittent fasting may be reassured in this regard, yet physicians can adopt the safe trial approach, where they allow the patients to fast, but with instructions such as when to break fasting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.